BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
2 Durner J, Beikler T, Watts DC, Becker M, Draenert ME. SARS-CoV-2 and regular patient treatment - from the use of rapid antigen testing up to treatment specific precaution measures. Head Face Med 2021;17:39. [PMID: 34481505 DOI: 10.1186/s13005-021-00289-9] [Reference Citation Analysis]
3 Kirchner T, Jaeckel E, Falk CS, Eiz-Vesper B, Taubert R. SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis. J Hepatol 2021;75:1506-9. [PMID: 34284030 DOI: 10.1016/j.jhep.2021.07.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Murer L, Volle R, Andriasyan V, Petkidis A, Gomez-Gonzalez A, Yang L, Meili N, Suomalainen M, Bauer M, Policarpo Sequeira D, Olszewski D, Georgi F, Kuttler F, Turcatti G, Greber UF. Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern. Curr Res Virol Sci 2022;3:100019. [PMID: 35072124 DOI: 10.1016/j.crviro.2022.100019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Moura J, Nascimento H, Ferreira I, Samões R, Teixeira C, Lopes D, Boleixa D, Sousa AP, Santos E, Silva AM. SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal. Multiple Sclerosis and Related Disorders 2022;63:103893. [DOI: 10.1016/j.msard.2022.103893] [Reference Citation Analysis]
6 de Oliveira Resende R, José de Oliveira V, Sousa Correa A, Trica de Araújo P, Akio Taketomi E. COVID-19 scenario and recommendations on the continuity of immunobiological therapy in patients with atopic asthma in Brazil and Latin America. Expert Rev Respir Med 2022. [PMID: 35034544 DOI: 10.1080/17476348.2022.2027758] [Reference Citation Analysis]
7 Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine. Ocul Immunol Inflamm 2022;:1-6. [PMID: 35167414 DOI: 10.1080/09273948.2022.2028293] [Reference Citation Analysis]
8 Hassan J, Haigh C, Ahmed T, Uddin MJ, Das DB. Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. Pharmaceutics 2022;14:1066. [DOI: 10.3390/pharmaceutics14051066] [Reference Citation Analysis]
9 Mahmud N, Anik MI, Hossain MK, Khan MI, Uddin S, Ashrafuzzaman M, Rahaman MM. Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments. ACS Appl Bio Mater 2022. [PMID: 35583460 DOI: 10.1021/acsabm.2c00123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]